Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
发明人:
HÖPKEN, Uta,REHM, Armin,BLUHM, Julia,UCKERT, Wolfgang
申请号：
AU2018321134
公开号：
AU2018321134A1
申请日:
2018.08.23
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a human CXC chemokine receptor type 5 (CXCR5) protein. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CXCR5, preferably pathogenic mature B cells and/or memory B cells, and/or pathogenic T cells and/or T follicular helper cells, in particular mature B cell non-Hodgkin's lymphoma (B-NHL), T cell non-Hodgkin's lymphoma, or autoantibody-dependent autoimmune disease, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis.
